Skip to content
buyWeak cluster of 2

GABELLI MARIO J bought $31k of GRX

director, other at Gabelli Healthcare & WellnessRx Trust. 3,000 shares at an average of $10.18, traded Nov 25, 2024, filed Nov 26, 2024.

Conviction score
28
Value
$31k
3,000 shares
Holdings after
312,226
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001271163-24-000069, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 25, 2024POpen-market purchase
Common Shares, Par Value $0.001indirect: GGCP, Inc.
+3,000$10.18$31k312,226Nov 26, 2024

Related signals

Other insiders at Gabelli Healthcare & WellnessRx Trust and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
32Weakbuy 2GRX
Gabelli Healthcare & WellnessRx Trust
Saba Capital Management, L.P.
owner
$199k20,408
34Weakbuy 2GRX
Gabelli Healthcare & WellnessRx Trust
GABELLI MARIO J
director, other
$41k4,000
40Moderatebuy 2GRX
Gabelli Healthcare & WellnessRx Trust
GABELLI MARIO J
director, other
$33k3,137
45Moderatebuy 2GRX
Gabelli Healthcare & WellnessRx Trust
GABELLI MARIO J
director, other
$83k7,863
15Weakbuy 2GRX
Gabelli Healthcare & WellnessRx Trust
Saba Capital Management, L.P.
owner
$14k1,312
23Weakbuy 2GRX
Gabelli Healthcare & WellnessRx Trust
GABELLI MARIO J
director, other
$1,154112
22Weakbuy 2GRX
Gabelli Healthcare & WellnessRx Trust
Saba Capital Management, L.P.
owner
$54k5,153
24Weakbuy 2GRX
Gabelli Healthcare & WellnessRx Trust
Saba Capital Management, L.P.
owner
$91k8,792
21Weakbuy 2GRX
Gabelli Healthcare & WellnessRx Trust
Saba Capital Management, L.P.
owner
$44k4,341
22Weakbuy 2GRX
Gabelli Healthcare & WellnessRx Trust
Saba Capital Management, L.P.
owner
$50k4,876

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.